1 min read
Add as a preferred source on Google

Bristol Myers Squibb Says KarXT Improved Alzheimer’s Psychosis Scores

The two Phase 3 trials found gains in hallucination and delusion scores, and the xanomeline and trospium chloride treatment was well tolerated.

An assessment sheet and pencil rest beside an empty clinic chair / TokenPost.ai
An assessment sheet and pencil rest beside an empty clinic chair / TokenPost.ai

Bristol Myers Squibb said results from two Phase 3 trials of KarXT showed improved scores for hallucinations and delusions associated with Alzheimer’s disease psychosis.

The company said KarXT, which contains xanomeline and trospium chloride, was well tolerated in the trials.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…